Harbour BioMed will work alongside BMS to progress and expedite the programmes aimed at the discovery of multi-specific antibodies. Credit: shisu_ka/Shutterstock.com.

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement focused on multi-specific antibody discovery and development.

Harbour BioMed will work alongside BMS to progress and expedite the programmes aimed at the discovery of the antibodies.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Harbour BioMed, in exchange, is eligible to obtain payments totalling $90m, with potential development and commercial milestone payments of up to $1.035bn.

It may also receive tiered royalties if BMS decides to proceed with all potential programmes.

Harbour BioMed is focused on new antibody therapeutic discovery and development in the fields of oncology and immunology.

It is expanding its pipeline through internal research and development, partnerships in joint discovery and development, and targeted acquisitions.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Harbour BioMed chairman, founder and CEO Jingsong Wang stated: “We are delighted to collaborate with BMS to advance next-generation multi-specific antibody discovery and development.

“This collaboration leverages our Harbour Mice fully human antibody technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential. Furthermore, the collaboration offers the possibility to utilise our established development capabilities to accelerate programmes by conducting early clinical trials in China.

“By uniting the strengths of our platform with BMS’s expertise in drug discovery and development, we look forward to progressing these programmes and delivering transformative therapies to patients worldwide.”

The Harbour Mice antibody technology platform is designed to generate fully human monoclonal antibodies in conventional two heavy and two light chain (H2L2) as well as the heavy chain-only (HCAb) formats.

In November 2025, Harbour BioMed and Evinova China formed a collaboration to utilise AI and digital technologies to enhance biologics development.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact